CTLA4 and melanoma: In particular, abscopal responses were documented in several melanoma patients when RT was associated with α-CTLA4 drugs as ipilimumab (49, 50), and/or α-PD-1/PD-L1 antibodies as nivolumab and pembrolizumab (51, 52).